3. >>Generics

Latuda, Other Generics Cleared In 2022 Helped Generate Nearly $19bn In Savings, US FDA Says

 
• By Derrick Gingery

Generics of the schizophrenia treatment Latuda generated more than $4bn in savings a year after their 2022 approval, according to an FDA study.

One generic generated more than $4bn in savings in the year after its 2022 approval (Shutterstock)

Generic drugs approved in 2022 saved patients nearly $19bn in their first year on the market, thanks in large part to follow-ons of Sumitomo Dainippon Pharma’s psychiatric drug Latuda (lurasidone hydrochloride).

Key Takeaways
  • Latuda savings were high because the generics entered a high-value sector.

The schizophrenia and bipolar disorder treatment’s generic versions saved more than $4.4bn, according to a US Food and Drug Administration...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Market Intelligence